Barclays analyst Peter Lawson reiterated a Hold rating on Relay Therapeutics (RLAY – Research Report) yesterday and set a price target of $15.00. The company’s shares closed yesterday at $10.57.
Lawson covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Exelixis, and Iovance Biotherapeutics. According to TipRanks, Lawson has an average return of 10.5% and a 46.69% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Relay Therapeutics with a $19.60 average price target.
See today’s best-performing stocks on TipRanks >>
RLAY market cap is currently $1.34B and has a P/E ratio of -3.94.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RLAY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Relay Therapeutics (RLAY) Company Description:
Relay Therapeutics Inc is a precision medicines company focused on enhancing small molecule therapeutic discovery in targeted oncology. Its pipeline products include RLY-1971 and RLY-4008 and among others.
Read More on RLAY:
- Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
- Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
- Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential
- Relay Therapeutics to sell 2.5M shares at $12.00 in private placement
